Alzamend Neuro, Inc. (ALZN)
NASDAQ: ALZN · Real-Time Price · USD
1.570
+0.010 (0.64%)
At close: Oct 31, 2024, 4:00 PM
1.610
+0.039 (2.52%)
After-hours: Oct 31, 2024, 6:13 PM EDT

Company Description

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders.

Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer’s, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient’s immunological system to combat Alzheimer’s disease.

The company has partnership agreement with Massachusetts General Hospital for the Phase II clinical trial of AL001.

Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Alzamend Neuro, Inc.
Alzamend Neuro logo
Country United States
Founded 2016
IPO Date Jun 15, 2021
Industry Biotechnology
Sector Healthcare
Employees 7
CEO Stephan Jackman

Contact Details

Address:
3480 Peachtree Road NE, Second Floor, Suite 103
Atlanta, Georgia 30326
United States
Phone 844 722 6333
Website alzamend.com

Stock Details

Ticker Symbol ALZN
Exchange NASDAQ
Fiscal Year May - April
Reporting Currency USD
IPO Price $5.00
CIK Code 0001677077
CUSIP Number 02262M308
ISIN Number US02262M4078
Employer ID 81-1822909
SIC Code 2834

Key Executives

Name Position
Stephan Jackman Chief Executive Officer and Director
Milton Charles Ault III Founder and Vice Chairman
David J. Katzoff Chief Financial Officer
Henry C. W. Nisser Esq. Executive Vice President, General Counsel and Director
Kenneth S. Cragun CPA Senior Vice President of Finance

Latest SEC Filings

Date Type Title
Oct 15, 2024 8-K Current Report
Oct 3, 2024 424B5 Filing
Oct 3, 2024 8-K Current Report
Sep 11, 2024 10-Q Quarterly Report
Jul 31, 2024 8-K Current Report
Jul 30, 2024 10-K Annual Report
Jul 30, 2024 NT 10-K Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Jul 12, 2024 8-K Current Report
Jul 10, 2024 424B3 Prospectus
Jul 9, 2024 EFFECT Notice of Effectiveness